AP NEWS

BioCorRx Provides BICX102 Grant Update

October 2, 2018

ANAHEIM, CA, Oct. 02, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided an update on the grant submitted to The National Institute on Drug Abuse (NIDA) for BICX102, the Company’s sustained release naltrexone implant for the treatment of alcohol and opioid use disorders.

The National Institute on Drug Abuse has reviewed the grant submission for BICX102 as scheduled. The company received a summary statement shortly after the scientific review which indicated an impact score of 27. Yesterday, the Company received a Just-In-Time (JIT) request from NIDA. According to the National Institute of Health (NIH) website, JIT “procedures allow certain elements of an application to be submitted later in the application process, after review when the application is under consideration for funding.” In the meantime, the Company has been moving forward with its development plans for BICX102 as previously disclosed.

Brady Granier, CEO, President, and Director of BioCorRx, Inc., commented, “Our grant application continues to advance through the process and we are quite pleased with the impact score received. We are further encouraged by the JIT request from NIH/NIDA and look forward to providing the requested information as soon as possible. Our team has already begun to compile the information needed.”

About BioCorRx

BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.

Safe Harbor Statement

The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

BioCorRx Inc. investors@BioCorRx.com 714-462-4880 Investor Relations: Crescendo Communications, LLC (212) 671-1020 x304 bicx@crescendo-ir.com

AP RADIO
Update hourly